Back
ESC Professional Premium Access

Effect of dronedarone versus placebo on atrial fibrillation progression: a post-hoc analysis from ATHENA trial

Session: Atrial fibrillation: rate or rhythm control
Topic: Rhythm Control, Antiarrhythmic Drugs
Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Professor Carina Blomstrom-Lundqvist

Orebro University Hospital, Orebro (Sweden)
40 presentations
8 followers

5 more presentations in this session

Association between early rhythm control and the risk of dementia in patients with atrial fibrillation and prior history of stroke: a nationwide population-based study

Speaker: Doctor S. Lee (Seoul, KR)

Access
Abstract
Slides
Like
Thumbnail

Dronedarone versus sotalol in patients with atrial fibrillation: a systematic literature review and network meta-analysis

Speaker: Professor J. Camm (London, GB)

Access
Abstract
Slides
Like
Thumbnail

Holistic approach of ablation versus antiarrhythmic drugs for efficacy, safety, and quality of life improvement in rhythm control of atrial fibrillation: a meta-analysis of randomized trials

Speaker: Mr G. Prana Jagannatha (Denpasar, ID)

Access
Abstract
Slides
Like
Thumbnail

Sex differences in the use of rhythm control strategies in patients with atrial fibrillation in FinACAF study

Speaker: Ms K. Kalatsova (Helsinki, FI)

Access
Abstract
Slides
Like
Thumbnail

Prevalence of modifiable risk factors and related poor cardiovascular outcomes following atrial fibrillation ablation

Speaker: Doctor K. Stout (Omaha, US)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Atrial fibrillation: rate or rhythm control

Speakers: Professor C. Blomstrom-Lundqvist, Doctor S. Lee, Professor J. Camm, Mr G. Prana Jagannatha, Ms K. Kalatsova...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources